GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines, ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Dr. Daniel Meltzer, a weight loss expert, suggests that it's possible to maintain weight loss after using GLP-1 medications by creating proper habits, including exercise and eating well. He emphasizes ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Maintaining weight loss after GLP-1 treatment is challenging — get expert tips on how to keep those pounds off for good.

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Abbreviations: BER, base excision repair; DSB, double-stand break; ERCC2, xeroderma pigmentosum complementing protein D; ERCC3, xeroderma pigmentosum complementing ...

There are no directors' trades from BetaShares S&P 500 Equal Weight ETF (QUS). Please use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities. FAQs ...